Form 4: Vigil Neuroscience CFO Disposes Shares Post-Sanofi Merger

Vigil Neuroscience's CFO, Jennifer Lynn Ziolkowski, disposed of all her common stock and stock options following the company's acquisition by Sanofi on August 5, 2025.

Summary

• The reporting person is Jennifer Lynn Ziolkowski, who serves as a Director and Chief Financial Officer of Vigil Neuroscience, Inc.
• On August 5, 2025, Ms. Ziolkowski disposed of 4,000 shares of Common Stock and 8 tranches of Stock Option Awards totaling 844,577 shares.
• These dispositions occurred as a direct result of the Agreement and Plan of Merger, where Vesper Acquisition Sub Inc., a wholly-owned subsidiary of Sanofi, merged with and into Vigil Neuroscience, Inc.
• At the effective time of the merger, each share of Vigil Neuroscience Common Stock was converted into the right to receive $8.00 in cash (the 'Closing Amount') plus one Contingent Value Right (CVR) representing the right to receive an additional $2.00 in cash, conditioned upon the satisfaction of a specific clinical milestone.
• All outstanding unvested stock options were accelerated and became fully vested at the effective time of the merger.
• Stock options with an exercise price less than the Closing Amount ($8.00) were cancelled and converted into a cash payment (total shares multiplied by the excess of the Closing Amount over the exercise price) plus one CVR per share.
• Stock options with an exercise price equal to or greater than the Closing Amount but less than $10.00 were cancelled and converted into one CVR per share, with a potential cash payment of $10.00 minus the exercise price if the milestone is achieved.

Sentiment

Score: 7

Explanation: The sentiment is positive for shareholders as the merger provides a clear exit strategy with immediate cash and potential upside via a CVR. For the company, it signifies a successful acquisition by a major pharmaceutical player, validating its assets.

Positives

• The merger provides a clear liquidity event for Vigil Neuroscience shareholders, offering an immediate cash payment of $8.00 per share.
• The inclusion of a Contingent Value Right (CVR) offers shareholders potential for an additional $2.00 per share, contingent on a clinical milestone, providing upside potential beyond the initial cash payment.
• All unvested stock options held by the reporting person were accelerated and fully vested, allowing option holders to realize value from their equity incentives as part of the merger terms.

Negatives

• Vigil Neuroscience, Inc. ceased to be an independent publicly traded company, becoming a wholly-owned subsidiary of Sanofi.
• Shareholders no longer participate in the future operational performance or growth of Vigil Neuroscience beyond the defined merger consideration and CVR terms.

Risks

• The Contingent Value Right (CVR) payment of $2.00 per share is not guaranteed and is conditioned upon the satisfaction of a specific clinical milestone, meaning the full $10.00 per share potential value may not be realized.

Future Outlook

The filing indicates the completion of the merger, resulting in Vigil Neuroscience, Inc. becoming a wholly-owned subsidiary of Sanofi. The future outlook for Vigil Neuroscience's assets and programs will now be determined by Sanofi's strategic direction, with a contingent payment tied to a specific clinical milestone.

Industry Context

This acquisition by Sanofi highlights the ongoing consolidation trend within the biotechnology and pharmaceutical sectors, where larger pharmaceutical companies acquire smaller biotech firms to bolster their pipelines and intellectual property, particularly in specialized therapeutic areas like neuroscience. The use of Contingent Value Rights (CVRs) is a common mechanism in such deals to bridge valuation gaps and share future development risks.

Comparison to Industry Standards

• The use of a Contingent Value Right (CVR) is a standard practice in biotech acquisitions, similar to deals like Bristol-Myers Squibb's acquisition of MyoKardia, where CVRs were used to provide additional payments based on regulatory approvals.
• The structure of accelerating unvested options upon merger completion is also a common provision in change-of-control clauses within executive compensation agreements across the industry.
• The per-share cash consideration of $8.00 plus a potential $2.00 CVR should be evaluated against Vigil Neuroscience's historical stock performance and analyst price targets prior to the merger announcement to assess its premium relative to comparable biotech acquisitions.

Stakeholder Impact

• Shareholders: Received cash and CVRs for their shares, providing a liquidity event and potential future upside.
• Employees: Unvested stock options were accelerated and vested, providing immediate value. The company is now a subsidiary of Sanofi, which may impact future employment terms and opportunities.
• Customers/Patients: The merger could potentially accelerate or alter the development and commercialization of Vigil Neuroscience's therapeutic programs under Sanofi's larger resources.

Next Steps

• Sanofi will integrate Vigil Neuroscience's operations and assets.
• Progress towards the clinical milestone for the CVR payment will be monitored.

Key Dates

Recommendation

The company has been acquired by Sanofi, and its shares have been converted into cash and Contingent Value Rights (CVRs). There is no longer an independent public market for Vigil Neuroscience shares. Existing shareholders have realized or will realize the merger consideration. The recommendation is 'hold' as the investment decision has been executed through the merger.

Keywords

Vigil Neuroscience, VIGL, Sanofi, Merger, Acquisition, SEC Form 4, Insider Transaction, Stock Options, Contingent Value Right, CVR, Biotechnology, Pharmaceuticals